tenapanor — United Healthcare
To reduce serum phosphorus in adults with chronic kidney disease (CKD) on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy
Preferred products
- calcium acetate
- sevelamer
- lanthanum
- Velphoro (sucroferric oxyhydroxide)
Initial criteria
- Diagnosis of chronic kidney disease (CKD)
- Patient is receiving dialysis
- Xphozah will be used as add-on therapy to reduce serum phosphorus
- Patient has had an inadequate response to phosphate binder therapy [e.g., calcium acetate, sevelamer, lanthanum, Velphoro (sucroferric oxyhydroxide)] OR Patient is intolerant to any dose of phosphate binder therapy
Reauthorization criteria
- Documentation of positive clinical response to Xphozah therapy
Approval duration
12 months